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Introduction: In approximately 60% of patients with NSCLC
who are receiving EGFR tyrosine kinase inhibitors, resistance
develops through the acquisition of EGFR T790M mutation.
We aimed to demonstrate that a highly sensitive and quan-
titative next-generation sequencing analysis of EGFR muta-
tions from urine and plasma specimens is feasible.
Methods: Short footprint mutation enrichment next-
generation sequencing assays were used to interrogate*Corresponding author.
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tation in urine or plasma specimens from patients enrolled
in TIGER-X (NCT01526928), a phase 1/2 clinical study of
rociletinib in previously treated patients with EGFR
mutant–positive advanced NSCLC.
Results: Of 63 patients, 60 had evaluable tissue specimens.
When the tissue result was used as a reference, the sensi-
tivity of EGFR mutation detection in urine was 72% (34 of
47 specimens) for T790M, 75% (12 of 16) for L858R, and
67% (28 of 42) for exon 19 deletions. With specimens thatfrom Clovis Oncology, Astra-Zeneca, Roche, and Boehringer-Ingelheim
outside the submitted work. Dr. Oxnard reports personal fees from
AstraZeneca, Clovis, Sysmex, Boehringer-Ingelheim, and Inivata
outside the submitted work; in addition, Dr. Oxnard has a patent
development and application of NSCLC plasma genotyping using
digital polymerase chain reaction pending. Dr. Gadgeel reports
personal fees from Roche/Genentech and AstraZeneca outside the
submitted work. The remaining author declares no conﬂict of interest.
Address for correspondence: Karen L. Reckamp, MD, City of Hope
Comprehensive Cancer Center, 1500 E Duarte Rd, Duarte, CA 91010.
E-mail: KRechamp@coh.org
ª 2016 International Association for the Study of Lung Cancer.
Published by Elsevier Inc. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
ISSN: 1556-0864
http://dx.doi.org/10.1016/j.jtho.2016.05.035
October 2016 Test for NSCLC-Mutated EGFR in Urine, Plasma 1691met a recommended volume of 90 to 100 mL, the sensitivity
was 93% (13 of 14 specimens) for T790M, 80% (four of ﬁve)
for L858R, and 83% (10 of 12) for exon 19 deletions. A
comparable sensitivity of EGFR mutation detection was
observed in plasma: 93% (38 of 41 specimens) for T790M,
100% (17 of 17) for L858R, and 87% (34 of 39) for exon
19 deletions. Together, urine and plasma testing identiﬁed
12 additional T790M-positive cases that were either unde-
tectable or inadequate by tissue test. In nine patients
monitored while receiving treatment with rociletinib, a rapid
decrease in urine T790M levels was observed by day 21.
Conclusions: DNA derived from NSCLC tumors can be
detected with high sensitivity in urine and plasma, enabling
diagnostic detection and monitoring of therapeutic
response from these noninvasive “liquid biopsy” samples.
 2016 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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A major challenge for assessing EGFR mutation status
in advanced NSCLC is the availability of suitable biopsy
tissue for molecular testing. Clinical studies suggest that
10% to 20% of all NSCLC biopsies are inadequate for
molecular analysis because of a lack of either sufﬁcient
tumor cells or ampliﬁable DNA.1,2 Biopsies also pose an
economic burden and health risk to patients, with biopsy-
associated patient morbidity (e.g., pneumothorax)
observed in 12% to 21% of image-guided transthoracic
needle tissue biopsies.3 Moreover, despite guidelines
recommending EGFR testing at diagnosis for guiding
ﬁrst-line treatment decisions,4,5 up to 25% of patients
with lung cancer receive treatment before EGFRmutation
assessment.6 Physicians cite tumor histologic features
(i.e., squamous), insufﬁcient tumor samples, poor health
status of the patient, long turnaround times for tests, and
patient’s desire to initiate therapy as reasons for failure
to undergo timely molecular testing.6
In NSCLC patients receiving ﬁrst-line tyrosine kinase
inhibitors (TKIs) targeting EGFR mutation–positive tu-
mors (i.e., erlotinib, geﬁtinib, and afatinib), resistance to
therapy develops through the emergence of a second
mutation in EGFR, T790M, in approximately 60% of
cases.7 Performance of a repeat biopsy of these patients
is still an emerging standard of care, and up to 25% of
patients may be medically ineligible owing to comor-
bidities or the lack of an accessible lesion.8 False-
negative results could occur with tissue biopsies, likelybecause of the underlying intratumoral and intertumoral
heterogeneity often associated with resistance mecha-
nisms such as T790M.9,10
Detection and monitoring of cancer-speciﬁc genomic
alterations in blood, speciﬁcally through the assessment
of circulating tumor DNA (ctDNA), is a minimally invasive
alternative to a tissue biopsy that has shown promise in
overcoming some of the challenges associated with
sampling from tissue.11 However, ctDNA presents its own
challenges for clinical diagnostics. It is highly fragmented,
may be very rare (<0.01%) as a proportion of all circu-
lating free nucleic acids in blood, and may be especially
difﬁcult to detect in certain cancers such as those local-
ized in the central nervous system.12,13 Highly sensitive
assays have been developed and continue to be improved
upon to address these challenges.13–24
ctDNA in the systemic circulation is eventually
excreted into urine, where it is thought to undergo
further degradation.25–28 Urine analysis is a truly
noninvasive alternative to tissue biopsy that integrates
DNA from multiple sites, thus potentially addressing the
challenges posed by tumor heterogeneity. To date, only a
limited number of published studies have examined the
feasibility of ctDNA detection from urine.25–28 Although
to our knowledge, none of these studies describe ctDNA
detection from the urine of patients with NSCLC, patient-
matched tissue and plasma and urine studies in colo-
rectal cancer (KRAS) and histiocytic disorders (BRAF)
indicate good concordance of DNA mutation status
across all three biopsy specimens.29–31
We report herein, for the ﬁrst time, the develop-
ment and characterization of an EGFR mutation
detection platform that identiﬁes L858R, exon 19 de-
letions, and T790M in ctDNA from both plasma
and urine samples from patients with NSCLC. We
evaluated the clinical performance of this platform in
matched pretreatment urine and plasma samples
and examined the feasibility of longitudinal moni-
toring of EGFR mutations from the urine of patients
with NSCLC in the TIGER-X study, which is a phase
1/2 study of the third-generation EGFR-TKI rociletinib
(CO-1686).Patients and Methods
Patients
A blinded, retrospective study was conducted on
matched urine and plasma specimens collected from 63
patients with stage IIIB to IV disease who were enrolled
in the TIGER-X trial (NCT01526928). Patients in TIGER-
X were required to have histologically or cytologically
conﬁrmed NSCLC and documented evidence of one or
more EGFR mutations. All patients signed an ethics
committee/institutional review board–approved consent
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X study design have been previously published.14,32Sample Collection and Processing
Tissue biopsies were collected within 60 days of
initiation of treatment with rociletinib. For all formalin-
ﬁxed, parafﬁn-embedded tissue specimens, tumor con-
tent was assessed by board-certiﬁed pathologists using
hematoxylin and eosin–stained slides. Tumor specimens
were considered evaluable if any tumor cells were
identiﬁed. For seven cases, DNA was extracted from one
5-mm section and central laboratory tissue testing was
performed with the cobas EGFR Mutation Test (Roche
Molecular Systems, Pleasanton, CA). For 55 cases, DNA
was extracted from two 5-mm sections and central
laboratory tissue testing was performed with the ther-
ascreen EGFR RGQ Polymerase Chain Reaction (PCR) Kit
(Qiagen, Valencia, CA). A local EGFR test result was used
for one case in which tissue was not submitted to the
central laboratory.
Blood and urine samples were obtained serially,
before administration of the ﬁrst dose, and with every 21-
day cycle of rociletinib treatment. Blood samples were
collected in K2 ethylenediaminetetraacetic acid BD
Vacutainer tubes (BD Biosciences, San Jose, CA), pro-
cessed into plasma within 30 minutes (1800 g for 10
minutes at 18C–23C), and stored at or below –70C. For
plasma DNA analysis, 1.5 to 4 mL of plasma was extracted
using the QIAamp DNA Circulating Nucleic Acid Kit
(Qiagen, Manchester, U.K.) according to the manufac-
turer’s instructions. Urine samples between 10 and 100
mL were collected in the clinic into 120-mL cups, sup-
plemented with preservative, and stored at or below
–70C. For urinary DNA extraction, urine was concen-
trated to 4 mL using Vivacell 100 concentrators (Sarto-
rius Corp., Bohemia, NY) and incubated with 700 mL of Q
Sepharose Fast Flow quaternary ammonium resin (GE
Healthcare, Pittsburgh, PA). Tubes were spun to collect
Sepharose and bound DNA. The pellet was resuspended
in a buffer containing guanidine hydrochloride and iso-
propanol, and the eluted DNA was collected as a ﬂow-
through using polypropylene chromatography columns
(BioRad Laboratories, Irvine, CA). The DNA was further
puriﬁed using QiaQuick columns (Qiagen, Hilden, Ger-
many). DNA in plasma and urine was quantitated using a
droplet digital PCR (ddPCR) assay that ampliﬁes a single-
copy RNaseP reference gene (QX200 ddPCR system, Bio-
Rad, CA) as described previously.30Urine and Plasma EGFR Mutation Analysis
Quantitative analysis of the T790M resistance muta-
tion and EGFR activating mutations (L858R and 69
deletion variants in exon 19) was performed using amutation enrichment PCR coupled with next-generation
sequencing (NGS) detection (Trovagene, San Diego, CA).
Selective ampliﬁcation of mutant fragments was accom-
plished by short amplicon (42–44 base pairs [bp])
kinetically driven PCR that ampliﬁes the mutant frag-
ments while suppressing the ampliﬁcation of the wild-
type (WT) sequence using a blocker oligonucleotide.
PCR primers contained a 30 gene-speciﬁc sequence and a
50 common sequence that was used in the subsequent
sample barcoding step. The PCR enrichment cycling
conditions utilized the initial 98C denaturation step
followed by the assay-speciﬁc 5 to 15 cycles of pre-
ampliﬁcation PCR and 17 to 32 cycles of mutation
enrichment PCR. Custom DNA sequencing libraries were
constructed and indexed using the Access Array System
for Illumina Sequencing Systems (Fluidigm Corp., San
Francisco, CA). The indexed libraries were pooled, diluted
to equimolar amounts with buffer and the PhiX Control
library, and sequenced to 200,000 coverage on an
Illumina MiSeq platform using 150-V3 sequencing kits
(Illumina, San Diego, CA). Primary image analysis, sec-
ondary base calling, and data quality assessment were
performed on the MiSeq instrument using RTAv1.18.54
and MiSeq Reporter v2.6.2.3 software (Illumina). The
analysis output ﬁles (FASTQ) from the runs were pro-
cessed using custom sequencing reads counting and
variant calling algorithms to tally the sums of total target
gene reads, WT, or mutant EGFR reads, which passed
predetermined sequence quality criteria (q score 20). A
custom quantiﬁcation algorithm was developed to accu-
rately determine the absolute number of mutant DNA
molecules in the source ctDNA sample. To that end, each
single multiplexed NGS run contained a set of standard
curve samples in addition to clinical samples and con-
trols. For each run the standard sample set was assayed
in parallel with patient samples starting with PCR
enrichment of mutant EGFR DNA followed by NGS. The
number of mutant copies detected was determined by
interpolation from a standard curve derived from the
standard sample set. To account for time of residency in
urine across serially collected samples, the results were
standardized by normalizing the number of copies
detected in the sample to a constant number of WT DNA
genome equivalents (GEqs) observed in an average urine
sample (i.e., 330 ng WT DNA ¼ 100,000 GEqs).Determination of ctDNA EGFR Mutation
Detection Cutoffs in Urine and Plasma
Clinical EGFR mutation detection cutoffs for urine
and plasma were determined for each assay by assessing
the level of nonspeciﬁc signal present, if any, from urine
and plasma DNA samples obtained from 54 to 64
unique healthy volunteers and metastatic patients with
October 2016 Test for NSCLC-Mutated EGFR in Urine, Plasma 1693non-NSCLC cancers (w50%:50%). Detection cutoffs were
standardized to100,000WTGEqsyielding adjusted clinical
detection cutoffs of 5.5, 5.5, and 12.6 copies per105 GEqs
for exon 19 deletions, L858R, and T790M, respectively.
Statistical Analysis
The correlation between input and output absolute
EGFR mutant copies in the analytical spike-in experi-
ments were examined using Spearman’s correlation,
which is robust against nonlinearity. Analysis of trends
observed in urine ctDNA EGFR signal upon patient
treatment with rociletinib was assessed using a two-
sided Wilcoxon’s paired two-sample test. p Values less
than 0.05 were considered statistically signiﬁcant. All
statistical analyses were carried out using R v3.2.3
computer software (R Foundation for Statistical
Computing, Vienna, Austria).Results
Development of EGFR Mutation Enrichment NGS
Assays for ctDNA
A three-pronged approach was taken to overcome
the inherent technical challenges of obtaining sensitive
detection and robust quantiﬁcation of ctDNA mutationsA Input Mutant Copies/ 
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Figure 1. Mutation (MT) enrichment next-generation sequencin
(WT) EGFR copies and output ratio of mutant-to-WT EGFR sequ
EGFR variants diluted in 60 ng (w18,180 genome equivalents
sequencing reads are means of 18 replicates from six
experiments performed on three different days by two operator
fraction of all copies or reads. (B) Data from (A) presented as m
lated as the percent of input mutant EGFR molecules divided byin plasma and urine. First, ultrashort footprint PCR as-
says were developed to increase the likelihood of
amplifying highly degraded ctDNA. Three ultrashort
footprint assays were developed to detect the most
common EGFR mutations: (1) a 42-bp EGFR exon 19
deletion assay recognizing 69 annotated deletions, (2) a
46-bp EGFR exon 21 L858R assay, and (3) a 44-bp
EGFR exon 20 T790M assay. Secondly, mutant ctDNA
fragments were enriched by a PCR-based method to
maximize sensitivity for detecting ctDNA mutations
having rare prevalence (i.e., w0.01%). Preferential PCR
enrichment of mutant EGFR ctDNA was accomplished by
using WT EGFR oligonucleotides that block the ability of
PCR primers to anneal and amplify WT EGFR DNA,
thereby increasing the likelihood of amplifying mutant
EGFR templates (see Patients and Methods). Lastly, ab-
solute ctDNA mutation copy numbers from a patient
sample were quantitated by NGS methodology. This was
achieved with the aid of a standard sample set spiked
with known copies of mutant EGFR molecules.
Enrichment performance of EGFR mutant DNA was
assessed by spiking ﬁve to 500 copies of mutant DNA
into 18,181 GEqs of WT DNA (0.028% to 2.7%). Fold
enrichment of EGFR mutant fragments increased as the
proportion of mutant versus WT fragments decreasedutant Sequencing Reads/WT Reads
(% Mutant)
Exon 19 deletions 
(c2235_2249del15p) T790M
7834/905 (90%) 8063/25367 (24%)
29593/991 (97%) 25793/28253 (48%)
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g. (A) Comparison between input ratio of mutant-to–wild-type
encing reads for ﬁve to 500 input mutant copies of indicated
) of WT DNA (mutation abundance of 0.028%–2.7%). Output
independent next-generation sequencing dilution series
s on two MiSeq instruments. Percent mutant is calculated as a
utation fold enrichment estimates. Fold enrichment is calcu-
the percentage of output mutant EGFR sequencing reads.
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sequencing libraries comprised 24% to 99.9% mutant
reads, thus enabling sensitive mutation detection by NGS
(Fig. 1A). For the three assays, 857- to 3214-fold
enrichment of EGFR mutation signal was obtained for
an input of ﬁve copies of mutant EGFR DNA within 60 ng
(18,181 GEqs) of WT DNA (Fig. 1B).Analytical Performance of ctDNA EGFR Mutation
Assays
The lower limit of detection (LLoD) for the EGFR
mutation assays was determined by using a statistical
model based on the Poisson distribution of rare
mutant DNA molecules within a series of highly
diluted EGFR mutant DNA samples (Supplementary
Digital Content). The observed frequency distribution
of the number of copies detected within 80 replicates
of samples with a mutant DNA spike-in level of one or
two expected mutant DNA copies per replicate was
within the 95% conﬁdence intervals of expectedFigure 2. Quantiﬁcation of EGFR mutant and wild-type DNA ble
Analysis of dilution series of indicated mutant EGFR variants s
gorithm was applied to transform the mutant EGFR sequencing r
whisker plots show the median (center line), 25th, and 75th per
the ﬁrst quartile minus 1.5 of the interquartile range (the third
1.5 of the interquartile range. (B) Interrun reproducibility of
enrichment next-generation sequencing assays for the dilution
presented. (C) Quantiﬁcation of twofold or 2.5-fold differences
fold ratio was calculated as the ratio of the two input mutant co
of two means for two measured mutant copy levels with a 95%frequency distribution within a Poisson model
(Supplementary Table 1). These results indicated a
LLoD of one copy in 18,181 WT GEqs (0.006%) for
EGFR exon 19 deletion and L858R assays and a LLoD
of two copies in 18,181 GEqs (0.01%) for the EGFR
T790M assay.
The analytical accuracy and reproducibility of the
EGFR mutation assays were determined by a dilution
series of six replicates of 0, 5, 10, 50, 100, and 250 copies
against a background of 18,181 WT DNA copies, span-
ning the linear range of the assays. The entire workﬂow
was replicated six times with three dilution series
replicates prepared by two different operators on three
different days for a total of 18 measurements at each
copy level; NGS analysis was performed on two different
Illumina MiSeq instruments. The Spearman correlation
between spiked-in absolute copy numbers (quantiﬁed by
ddPCR) versus detected copy numbers (quantiﬁed by
mutation enrichment NGS) ranged from 0.967 to 0.981
for the EGFR mutation assays (Fig. 2A). The mean coef-
ﬁcient of variation percentage was 34.5% across thends by mutation enrichment next-generation sequencing. (A)
piked into 60 ng (w18,180 GEq) of WT DNA. An analysis al-
eads into the absolute mutant copies detected. The box-and-
centiles (box) with the connecting “whiskers” extending from
quartile minus the ﬁrst quartile) and the third quartile plus
the EGFR exon 19 deletions, L858R, and T790M mutation
series shown in (A). Coefﬁcient of variation percent (CV%) is
between subsequent mutant copy input levels. The expected
py levels. The observed fold ratio was calculated as the ratio
conﬁdence interval (CI).
Table 1. Patient Demographic and Baseline Characteristics
Characteristics
Patients in TIGER-X
with Pretreatment
Urine Samples
(N ¼ 63)
Age, y
Median 64
Range 40–85
Sex, n (%)
Female 45 (71.4)
Male 18 (28.6)
Race, n (%)
October 2016 Test for NSCLC-Mutated EGFR in Urine, Plasma 1695reportable range of 5 to 250 copies for all three EGFR
mutation assays (yielding an adjusted quantiﬁable range
of 27.5 to 1375 copies per 100,000 GEqs), with the
highest coefﬁcient of variation percentage of 47.4% to
60.7% observed at the lowest input of ﬁve copies likely
owing to Poisson limitations (Fig. 2B). Assay fold-
discrimination performance was examined by
comparing the expected copy ratio between two
consecutive dilutions to the observed copy ratio
(Fig. 2C). Known twofold and 2.5-fold differences within
the dilution series were maintained and detected for all
three EGFR mutation assays (Fig. 2C).Asian 17 (27.0)
Black/African American 1 (1.6)
White 44 (69.8)
Other 0
Missing 1 (1.6)
Histologic diagnosis, n (%)
Adenocarcinoma 63 (100)
ECOG at study entry, n (%0)
0 18 (28.6)
1 45 (71.4)
No. previous therapies at baseline, n (%)
0 0
1 21 (33.3)
2 11 (17.5)
3 7 (11.1)
4 9 (14.3)
5þ 15 (23.8)
No. previous EGFR TKIs at baseline, n (%)
1 34 (54.0)
2 17 (27.0)
3 12 (19.0)
Smoking history, n (%)
Current smoker 1 (1.6)
Former smoker 22 (34.9)
Never-smoker 40 (63.5)
TIGER-X, Study to Evaluate Safety, Pharmacokinetics, and Efﬁcacy of
Rociletinib (CO-1686) in Previously Treated Mutant EGFR in NSCLC
Patients; ECOG, Eastern Cooperative Oncology Group; TKI, tyrosine kinase
inhibitor.Clinical Performance of ctDNA EGFR Mutation
Assays in Urine
Matched baseline tumor tissue biopsies and urine
samples were obtained from the ﬁrst 63 consecutive
patients in TIGER-X who agreed to optional pretreat-
ment urine sample collection. TIGER-X was a phase
1/2 trial of rociletinib in patients with stage IIIB to IV
NSCLC who had been treated with at least one prior
EGFR inhibitor and had an EGFR activating mutation
in their medical record. The clinical characteristics of
the 63 patients are shown in Table 1. Tumor tissue
was processed by a central laboratory for EGFR mu-
tation testing. Of the 63 tumor tissue biopsy samples,
60 were adequate for analysis, with 47 positive for
T790M, 16 positive for L858R, and 42 positive for
exon 19 deletion mutations. Thirteen of 60 evaluable
cases were negative for T790M, and two of 60 cases
were negative for either L858R or exon 19 deletion
mutation by central laboratory testing. Urine volumes
ranged from 10 to 100 mL, with 19 of 63 samples
meeting the prespeciﬁed criteria for the recom-
mended urine volume of 90 to 100 mL. Tumor tissue
testing was used as a reference standard. For all
samples (volumes 10–100 mL), the sensitivity of the
urine assays for EGFR mutation detection was 72%
(34 of 47 samples) for T790M, 75% (12 of 16) for
L858R, and 67% (28 of 42) for exon 19 deletion
mutations (Table 2). For samples with the recom-
mended urine volume of 90 to 100 mL, the sensitivity
of EGFR mutation detection was 93% (13 of 14) for
T790M, 80% (four of ﬁve) for L858R, and 83% (10 of
12) for exon 19 deletions (see Table 2). For urine
samples with lower volumes (10–89 mL), the sensi-
tivity for EGFR mutation detection was 64% (21 of 33)
for T790M, 73% (eight of 11) for L858R, and 60% (18
of 30) for exon 19 deletions (see Table 2).
The speciﬁcity of the EGFR urine assays was deter-
mined using urine samples obtained from healthy do-
nors and patients with non-NSCLC metastatic cancers
(see Patients and Methods) and was 96% for T790M,100% for L858R, and 94% for the exon 19 deletion
mutations (see Table 2).Clinical Performance of ctDNA EGFR Mutation
Assays in Plasma
Plasma was available for 60 of the 63 patients. When
tumor tissue testing results were used as a reference
standard, the detection sensitivity of the assays in
plasma was 93% (38 of 41 samples [three of 44 available
plasma samples failed NGS]) for T790M, 100% (17 of 17
samples) for L858R, and 87% (34 of 39 samples) for
exon 19 deletions (see Table 2). The speciﬁcity of the
EGFR plasma tests was determined using plasma sam-
ples obtained from healthy donors and patients with
non-NSCLC metastatic cancers and was 94% for T790M,
Table 2. Performance of Mutation Enrichment NGS Assays
for Detection of EGFR Mutations in Urine and Plasma
Characteristics Specimen Type Value, n %
T790M
Sensitivity All urine volumes, 10–100 mL 72% (34 of 47)
Urine volumes, 90–100 mLa 93% (13 of 14)
Urine volumes, 10–89 mL 64% (21 of 33)
Plasma 93% (38 of 41)
Speciﬁcity Urine 96% (54 of 56)
Plasma 94% (60 of 64)
L858R
Sensitivity All urine volumes, 10–100 mL 75% (12 of 16)
Urine volumes, 90–100 mLa 80% (4 of 5)
Urine volumes, 10–89 mL 73% (8 of 11)
Plasma 100% (17 of 17)
Speciﬁcity Urine 100% (50 of 50)
Plasma 100% (48 of 48)
Exon 19 deletions
Sensitivity All urine volumes, 10–100 mL 67% (28 of 42)
Urine, volumes 90–100 mLa 83% (10 of 12)
Urine, volumes 10–89 mL 60% (18 of 30)
Plasma 87% (34 of 39)
Speciﬁcity Urine 94% (47 of 50)
Plasma 96% (47 of 49)
aRecommended urine volume: 90 mL.
NGS, next-generation sequencing.
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tions (see Table 2).Urine and Plasma Identify Additional EGFR
T790M–Positive Cases Undetectable by Tissue
Biopsy
Contingency tables for the EGFR mutation detection
in urine, plasma, and tissue are presented in Figure 3.
For all urine sample volumes, there were 11 cases that
were urine T790M–positive but tumor tissue T790M–
negative or tissue sample–inadequate (Fig. 3A). Of these
11 cases, 10 were also T790M positive in plasma (one
sample was T790M negative in plasma). Similarly, of the
11 discordant cases that were plasma T790M–positive
but tissue T790M–negative or tissue sample–inadequate,
10 were also positive by urine T790M testing (one
sample was T790M negative in urine). Together, urine
and plasma T790M testing identiﬁed a higher proportion
of positive cases (89% [56 of 63) than did tissue testing
alone (75% [47 of 63]).
When 60 cases with all three patient-matched
specimen types were considered, urine analysis iden-
tiﬁed seven T790M cases not detected or failed in
plasma and 11 cases were not detected by tissue or
found to be tissue sample–inadequate (Fig. 3D). Anal-
ysis of urine and blood combined detected T790M in
93% of patients (56 of 60). Tissue analysis alone
detected T790M in 73% of patients (44 of 60). Four of60 cases were negative according to testing of tissue,
plasma, and urine samples.Association of EGFR T790M Levels in Urine with
Patient Response to Rociletinib
Recent studies have suggested that the extent to
which plasma EGFR mutation levels drop after intro-
duction of EGFR TKI therapy may predict depth of
response.14,16 To assess this relationship in urine, lon-
gitudinal urine samples were obtained from 15 patients
treated with therapeutic doses of rociletinib (500, 625,
750, or 1000 mg twice daily [hydrobromide formula-
tion]). Of these 15 patients, ﬁve had progressive
disease as their best overall conﬁrmed response and 10
patients had either stable disease or a partial response
(PR) as their overall conﬁrmed response. Among these,
nine patients were identiﬁed with quantiﬁable levels of
baseline T790M in urine (>27.5 copies per 100,000
GEqs), with seven experiencing PR or stable disease as
best overall conﬁrmed response and two with progres-
sive disease as best overall conﬁrmed response. For
all nine patients, there was a signiﬁcant decrease in
T790M levels in urine after cycle 1 relative to baseline
irrespective of best overall conﬁrmed response
(range 51% to 100%; p ¼ 0.0091, two-sided
Wilcoxon test; p < 0.0001, two-sided t-test) (Fig. 4A
and B). However, in the two patients with progressive
disease, there was an observed attenuated decrease
(51% and 70%) compared with in patients with PR
and stable disease as best overall conﬁrmed response
(range 83% to 100%).
Discussion
Herein we have described a highly sensitive method
for detection of actionable EGFR mutations in the urine
and plasma of patients with advanced NSCLC. In our
study cohort of relapsed patients, the sensitivity of
EGFR mutation detection in urine with tumor as a
reference was 72% (34 of 47) for T790M, 67% (28 of
42) for exon 19 deletions, and 75% (12 of 16) for
L858R mutations (all urine volumes). A higher sensi-
tivity was achieved with urine samples at the recom-
mended volume of 90 to 100 mL as compared with
urine volumes less than 90 mL: 93% (13 of 14) for
T790M, 71% (ﬁve of seven) for L858R, and 83% (10 of
12) for exon 19 deletions (90–100 mL) versus 64% (21
of 33) for T790M, 72% (eight of 11) for L858R, and
60% (18 of 30) for the exon 19 deletion mutations
(volumes of 10–89 mL). The speciﬁcity of the urine
EGFR assays in healthy volunteers or patients without
NSCLC was 96% for T790M, 100% for L858R, and 94%
for exon 19 deletion mutations. To our knowledge, this
study represents the ﬁrst successful demonstration of
AB
C
10-100 mL urine
T790M Plasma, n TotalPositive Negative Failed
Urine, n Positive 38 4 3 45Negative 11 4 0 15
Total 49 8 3 60
Urine vs Tissue
Urine vs Plasma
Plasma vs Tissue
T790M FFPE Tumor, n TotalPositive Negative Inadequate
Plasma, n Positive 38 9 2 49Negative 3 4 1 8
Failed 3 0 0 3
Total 44 13 3 60
D
T790M-posiƟve cases10-100 mL urine
T790M FFPE Tumor, n TotalPositive Negative Inadequate
Urine, n Positive 34 9 2 45Negative 13 4 1 18
Total 47 13 3 63
Positive by any one specimen type: 56 of 60 (93%)
Positive by tissue: 44 of 60 (73%)
Positive by plasma: 49 of 60 (82%)
Positive by urine: 45 of 60 (75%)
Positive by urine and plasma combined: 56 of 60 (93%)
Negative by any one specimen type: 4 of 60 (7%)
UrineTissue
Plasma
10
10
10
1
28
6
Figure 3. Contingency tables for the analysis of EGFR T790M mutation in matched tumor, urine, and plasma specimens from
patients enrolled in the TIGER-X clinical trial. (A) Urine versus tumor analysis of T790M in 63 matched tumor and urine
specimens. (B) Plasma versus tumor analysis of T790M in 60 matched tumor and plasma specimens. (C) Urine versus plasma
analysis of T790M in 60 matched urine and plasma specimens. (D) Venn diagram showing T790M-positive status of 60 cases
with available matched tumor, plasma, and urine specimens. Four cases not identiﬁed as T790M-positive by tumor, plasma, or
urine are not depicted in the diagram. FFPE, formalin-ﬁxed, parafﬁn-embedded.
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The transrenal clearance of systemically derived DNA
was ﬁrst demonstrated in 2000 by Botezatu et al. who
detected male-speciﬁc sequences in the urine of womenFigure 4. Longitudinal dynamics of EGFR T790M signal in urine
urinary T790M signal from baseline was observed after one cy
letinib. (B) Clinical outcomes of patients in the longitudina
by investigator. For patient 2, percent change in urine T790M f
SD, stable disease.transfused with male blood or pregnant with male fe-
tuses.25 In addition, this pioneering work demonstrated
that circulating nucleic acid of tumor origin could be
identiﬁed in the urine of patients with cancer, specif-
ically those with colorectal or pancreatic cancer.25of patients treated with rociletinib. (A) A rapid decrease in
cle of treatment (21 days) in all patients treated with roci-
l analysis. Best overall conﬁrmed response was assessed
rom baseline was estimated at day 42. PR, partial response;
1698 Reckamp et al Journal of Thoracic Oncology Vol. 11 No. 10Further studies suggested that the size of the systemi-
cally derived DNA fragments in urine can range from
approximately 35 to 250 bp.27,33–35 Subsequently, an
anion exchange–based urinary DNA isolation technique
coupled with ultrashort amplicon PCR detection was
developed to maximize the detection of systemically
derived DNA.27,33,34 The method described in the pre-
sent study builds on this work, incorporating an anion
exchange–based method to preferentially isolate low-
molecular-weight DNA from urine, short amplicon PCR
with WT DNA suppression for mutation enrichment, and
ultradeep sequencing to further enhance the identiﬁca-
tion of rare mutations. Using this approach, we show
single-copy detection with spiked sample material.
Our methodology may have also contributed to the
high clinical sensitivity that we observed for detecting
EGFR mutations in plasma (range 87%–100%), which
compares favorably with the published performance of
real-time and ddPCR platforms. For example, T790M
detection sensitivity in patients who experienced a
relapse while receiving ﬁrst-line EGFR TKIs was shown
to range between 64% and 73% for the cobas test (a test
platform based on real-time PCR), 73% to 81% for
BEAMing (Beads, Emulsion, Ampliﬁcation, and Mag-
netics, a technology based on digital PCR), and 77% for
the ddPCR platform.13,18,24 In the same studies, the
sensitivity for detection of activating EGFR mutations
was 73% to 84% for the cobas test, 82% to 84% for the
BEAMing assay, and 74% to 82% for the ddPCR plat-
form.14,18,24 In ﬁve recent trials in patients with previ-
ously untreated NSCLC (NCT01203917, FASTACT-2,
TRIGGER, EUROTAC, and NCT02279004), the sensitivity
for detection of EGFR exon 19 deletions and L858R
mutations in plasma was 78% for a real-time peptide
nucleic acid clamp test, 69% to 86% for a ddPCR test,
62% to 68% for the therascreen EGFR RGQ PCR test, and
62% to 100% for the cobas test.2,15,16,22,24 The speci-
ﬁcities of our plasma assays in healthy volunteers and
patients without NSCLC were 94% to 100%, which are
similar to that found in urine. Limitations of this study
include a small sample size for urine with volumes of 90
to 100 mL and a less than 100% assay speciﬁcity.
Analysis of a larger cohort of patients is under way. An
improved error correction bioinformatics algorithm is
being developed to further increase assay speciﬁcity.
Assay sensitivity in the present study was calculated
using tumor as the reference sample type. This method
has limitations, particularly when applied to resistance
mutations such as T790M that will have a signiﬁcant
false-negative rate in analysis of biopsy samples owing to
tumor heterogeneity and low tumor cellularity.9,10,14,24
In our study, the combination of urine and plasma
testing identiﬁed 12 T790M-positive cases that were
undetectable by central laboratory testing of tumortissue. Although 10 of the 12 cases were positive by both
ctDNA specimen types, one case each was unique to
plasma and urine. Urine may therefore provide comple-
mentary information about a patient’s mutational status
that is not captured by plasma or tissue tests. These re-
sults indicate for the ﬁrst time that either urine or plasma
T790M testing may be considered as an alternative to
tissue biopsy testing. Urine testing can be the preferable
option because it represents a truly noninvasive alter-
native that can be collected in a patient’s own home, and
the results of both diagnostic and monitoring testing can
be made available without scheduling visits to the clinic.
Given the ease of sample collection, urine holds
promise for the serial monitoring of patients. Studies in
plasma have already shown that early changes in ctDNA
may predict response to targeted therapies and that
emergence of resistance mutations can be identiﬁed
before radiographic progression.12,14,15,19,23 Reported
here, T790M levels in urine rapidly decreased to a frac-
tion of their pretreatment levels in patients treated with
rociletinib, regardless of RECIST response status. These
data are consistent with previous ﬁndings in plasma and
suggest that rociletinib reduces proliferation and conse-
quently turnover of T790M-positive clones even in pa-
tients with primary resistance.9,14 It is an intriguing
observation that there was an attenuated decrease in
T790M levels for the two patients with progressive dis-
ease as best overall response. Further urine analysis of a
substantially larger cohort of patients from the TIGER-X
study is ongoing and should further inform the utility of
longitudinal monitoring in this patient population.
In conclusion, our data demonstrate that urine
testing using the mutation enrichment NGS method
successfully identiﬁes EGFR mutations in patients with
metastatic NSCLC and has high concordance with tumor
and plasma, suggesting that EGFR mutation detection
from urine or plasma should be considered as a viable
approach for assessing EGFR mutation status.
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